Issues at a former Catalent plant now owned by Novo Nordisk have derailed another FDA application. Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.
Novo’s troubled Indiana plant claims another victim as FDA rejects Incyte’s lung cancer application
Latest from Blog
Nutrition nonprofit holds roundtable discussion in Fitzgerald
While their focus may be on providing aid around the globe, MANA Nutrition is doing what they can to keep American farmers in mind. Post Views: 2
ROFI Drives New Approach to Crop Nutrition
With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Tippecanoe schools hire new nutrition leader
Alison Jordan has been hired as the new nutrition services director for Tippecanoe School Corporation, overseeing meals for 20 schools. Post Views: 2
Gift Nets Scholarships, Nutrition for Men’s Soccer
The $110,000 gift comes from the New Hope Foundation, which works to create opportunities for individuals and families in need. Post Views: 1
Adia clears ethics review for CKD stem cell trial, recruitment next
The planned trial targets adults with Stage 2-4 chronic kidney disease and will track kidney function and inflammation markers. Recruitment starts after listing. Post Views: 1